Hefei Lifeon Pharmaceutical Co., Ltd.

003020

CNE100004BD9

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 23/05/2024 am IST			5-day change	1st Jan Change
24.76 ^CNY	+2.65%		+4.47%	-12.04%

21/05	Lifeon Pharmaceutical's Unit Gets Marketing Authorization for Loxoprofen Sodium Oral Solution	MT
29/04	Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Hefei Lifeon Pharmaceutical Co., Ltd., Hefei Xinchen Enterprise Management Consulting Co., Ltd., Li Chao and Deng Xiaojuan agreed to acquire Hefei Noratech Pharmaceuticals Co., Ltd. from Roaring Success Ltd and Hefei Xinchen Enterprise Management Consulting Co., Ltd. for CNY 72 million.

October 31, 2023

Hefei Lifeon Pharmaceutical Co., Ltd. (SZSE:003020), Hefei Xinchen Enterprise Management Consulting Co., Ltd., Li Chao and Deng Xiaojuan agreed to acquire Hefei Noratech Pharmaceuticals Co., Ltd. from Roaring Success Ltd and Hefei Xinchen Enterprise Management Consulting Co., Ltd. for CNY 72 million on October 29, 2023. As of June 30, 2023, Hefei Noratech Pharmaceuticals Co., Ltd. generated total assets of CNY 136.3 million and net assets of CNY 75.7 million.

Latest news about Hefei Lifeon Pharmaceutical Co., Ltd.

Lifeon Pharmaceutical's Unit Gets Marketing Authorization for Loxoprofen Sodium Oral Solution	21/05	MT
Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04	CI
Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	22/04	CI
Lifeon Pharma’s Diabetes Drugs Pass China Consistency Evaluation	21/12	MT
Certain A Shares of Hefei Lifeon Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 15-DEC-2023.	15/12	CI
Lifeon Pharmaceutical Gets Chinese Drug Regulator's Nod to Market Doxazosin Mesylate	07/12	MT
Hefei Lifeon Pharmaceutical Co., Ltd. Approves Election of Shi Jing as an Independent Director	17/11	CI
Hefei Lifeon Pharmaceutical Co., Ltd., Hefei Xinchen Enterprise Management Consulting Co., Ltd., Li Chao and Deng Xiaojuan agreed to acquire Hefei Noratech Pharmaceuticals Co., Ltd. from Roaring Success Ltd and Hefei Xinchen Enterprise Management Consulting Co., Ltd. for CNY 72 million.	31/23/31	CI
Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/23/30	CI
Hefei Lifeon Pharmaceutical Co., Ltd.(XSEC:003020) added to S&P Global BMI Index	18/23/18	CI
Hefei Lifeon Pharmaceutical Co., Ltd. signed equity transfer agreement to acquire 51% stake in Anhui Joyfar Pharmaceutical Co. Ltd. from Beijing Huixu Jintong Investment Center (Limited Partnership), Beijing Huixu Jintai Investment Center (Limited Partnership), Gong Tonglin, Shen Jun, Zhao Shoutian and Ouyang Hanlin for approximately CNY 220 million.	29/23/29	CI
Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	28/23/28	CI
Hefei Lifeon Pharmaceutical Co., Ltd. Declares Cash Dividend on A Shares for 2022, Payable on May 24, 2023	18/23/18	CI
Hefei Lifeon Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2023	10/23/10	CI
Hefei Lifeon Pharmaceutical Co., Ltd. Proposes Final Dividend for 2022	19/23/19	CI
Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	17/23/17	CI
Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	17/23/17	CI
Hefei Lifeon Pharma’s Blood Pressure Drug Joins Bid For Inclusion in China’s Drug Procurement Program	30/23/30	MT
Worldunion Group CFO Resigns; Successor Named	30/23/30	MT
Anhui Lifeon Pharmaceutical Co., Ltd. announced that it expects to receive CNY 113 million in funding from Hefei Lifeon Pharmaceutical Co., Ltd.	02/23/02	CI
Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	30/22/30	CI
Hefei Lifeon Pharmaceutical Co., Ltd. Announces Board Appointments	01/22/01	CI
Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	26/22/26	CI
Pingtan Wenzhou Ruiji Investment Partnership Enterprise and Zhuzhou Wenzhou Junzhe Venture Capital Partnership Enterprise (L.P.) managed by Shanghai Wenzhou Investment Management Co., Ltd. completed the acquisition of 4.94% stake in Minova Pharma from Hefei Lifeon Pharmaceutical Co., Ltd. for approximately CNY 32.1 million.	12/22/12	CI
Hefei Lifeon Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2021R	17/22/17	CI

Chart Hefei Lifeon Pharmaceutical Co., Ltd.

Duration

Period

Chart Hefei Lifeon Pharmaceutical Co., Ltd.

More charts

Company Profile

Hefei Lifeon Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of pharmaceutical preparations and active pharmaceutical ingredients (APIs). The Company is also engaged in the wholesale and retailing of pharmaceuticals and medical devices. The Company's main products involve cardiovascular drugs, digestive system drugs and skin topical drugs.

Sector

Pharmaceuticals

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Hefei Lifeon Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

24.76

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HEFEI LIFEON PHARMACEUTICAL CO., LTD.	-12.04%	546M
ELI LILLY AND COMPANY	+38.69%	728B
NOVO NORDISK A/S	+34.26%	603B
JOHNSON & JOHNSON	-4.49%	360B
MERCK & CO., INC.	+20.24%	332B
ABBVIE INC.	+2.12%	279B
ASTRAZENECA PLC	+16.28%	244B
NOVARTIS AG	+7.87%	207B
ROCHE HOLDING AG	-5.24%	205B
PFIZER, INC.	-0.35%	163B

Other Pharmaceuticals